
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
Boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development are top of mind for life science CEOs.
Fielded in September 2025 and released on Oct. 14, 2025, the
“Despite a climate of uncertainty, life science leaders are decisively investing in AI to drive innovation and product development,” said
Following are some key findings reflecting the opinions and experiences of a high percentage of the CEOs surveyed.
Decisive AI investment
AI is a top investment priority for 75% of life sciences CEOs, up sharply from 60% in 2024. Financially, 73% anticipate spending 10–20% of their budget on AI in the next 12 months.
Rapid ROI expectations
A majority of leaders (65%) anticipate seeing a return on their AI implementation investment within one to three years.
Targeted funding for operations
Investment is highly concentrated in operational areas: 80% are investing in agentic AI, and 79% are investing in AI in products and services and for intelligent manufacturing.
Workforce upskilling is critical
AI workforce readiness or upskilling is cited by 85% of CEOs as a trend impacting organizational prosperity during the next three years.
Focus on talent retention
More than three-quarters (77%) of organizations are modifying their long-term workforce strategy (2–5 years) to focus on retaining and re-training high potential talent.
Rising ethical concerns
Ethical challenges are cited by 66% of organizations as a barrier to AI implementation, an increase from 58% in 2024.
Regulatory demands impact prosperity
Regulatory demands are cited by 74% of CEOs as a trend that will impact prosperity during the next three years.
High security concerns
Six out of 10 CEOs are “extremely concerned” about fraud detection and prevention, and 47% are equally concerned about identity theft and data privacy.
References
1. KPMG. Life Sciences 2025 CEO Findings. Provided via email correspondence on Oct. 13, 2025.
2. Statement provided via email correspondence on Oct. 13, 2025.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.